Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Viewpoint - Analysts project Biogen Inc. (BIIB) will report quarterly earnings of $3.45 per share, a 17% increase year over year, with revenues expected to reach$ 2.42 billion, reflecting a 1.3% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.7% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate that revenue from the product TYSABRI for Multiple Sclerosis (MS) will be $394.22 million, showing a year-over-year decline of 15.2% [5]. - Revenue from SPINRAZA for Rare Diseases is projected at$ 416.10 million, indicating a 0.9% increase year over year [5]. - Revenue from Anti-CD20 therapeutic programs is expected to be $442.52 million, reflecting a 1.5% increase year over year [6]. - Total net product revenue is estimated to be$ 1.81 billion, suggesting a year-over-year decline of 1% [6]. Specific Product Revenue Estimates - Revenue from TYSABRI in the United States is projected at $214.54 million, a decrease of 13.4% from the prior year [7]. - Revenue from TECFIDERA in the Rest of the World is expected to reach$ 181.80 million, indicating a 0.7% increase year over year [7]. - Revenue from TYSABRI in the Rest of the World is estimated at $177.74 million, reflecting an 18.1% decline year over year [8]. - Revenue from TECFIDERA in the United States is projected at$ 39.62 million, showing a significant decrease of 37.9% from the prior year [8]. - Revenue from SPINRAZA in the United States is expected to be $156.54 million, indicating a slight decline of 0.6% year over year [9]. - Revenue from Interferon for MS in the Rest of the World is estimated at$ 97.93 million, reflecting a 10.7% decline year over year [9]. - Revenue from Interferon for MS in the United States is projected at $140.99 million, indicating a 17.2% decline year over year [10]. - Revenue from SPINRAZA in the Rest of the World is expected to be$ 256.08 million, reflecting a 0.4% increase year over year [10]. Stock Performance - Biogen shares have decreased by 5.6% over the past month, contrasting with a 1.9% increase in the Zacks S&P 500 composite [10].